CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.The findings, published simultaneously in The New England Journal of Medicine, showed efficacy across all patient subgroups.
CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.Results of the randomized phase 3 SWOG S1826 trial, presented at ASCO Annual Meeting, showed a 52% improvement in PFS with the nivolumab (Opdivo, Bristol Myers
CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.“The most important point of PRODIGE 23 is the overall survival benefit,” Thierry Conroy, MD, of the department of medical oncology at Institut de
CHICAGO — Adding talazoparib to atezolizumab as maintenance treatment after front-line chemoimmunotherapy significantly lengthened PFS among adults with SLFN11-positive extensive-stage small cell lung cancer, according to a phase 2 study.Results of the randomized trial presented at ASCO Annual Meeting suggested that a biomarker-based approach to treating small cell lung cancer is feasible
CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO Annual Meeting.“Neoadjuvant FOLFIRINOX showed acceptable safety and resectability rates,” Knut Jørgen Labori, MD, PhD, of the department of hepato-pancreato-biliary surgery at Oslo